Universal screening of women with gynecologic malignancies for early palliative care decreased the use of aggressive measures at the end of life.
Living in a high-poverty region is associated with lower access to obesity-related self-care resources.
There are 18 core priority symptoms that should be routinely assessed in patients with recurrent ovarian cancer to provide higher quality of care.
Nurse-guided and self-directed web-based symptom management interventions (WRITE Symptoms) improved symptom controllability among women with recurrent ovarian cancer.
Presence of 1 risk factor or 2 or more risk factors is associated with non-home discharge after hysterectomy for gynecologic malignancy.
Study finds that instituting a health system-wide quality metric, such as postoperative hospital readmission rate, may be inconsistent with long-term clinical outcomes goals.
Perioperative Pain Control Reduces Need for Postoperative Narcotics After Hysterectomy for Uterine CancerMarch 15, 2017
Preoperative intravenous acetaminophen plus local infiltration of LB during hysterectomy and surgical staging of uterine cancer may reduce the need for postoperative narcotics.
Perioperative celecoxib use during hysterectomy may reduce the need for oral narcotics after hospital discharge.
Use of chemotherapy or vaginal brachytherapy (VBT) may improve survival among patients with early-stage uterine papillary serous carcinoma.
Nearly 3 in 10 cervical cancer survivors were still using opioids at 6 months after completing radiotherapy.
Nonadherence to NCCN guideline treatment recommendations was strongly associated with decreased survival from early-stage cervical cancer.
The top reasons for not initiating HPV vaccination are necessity, safety, and knowledge, rather than a lack of discussions on sexuality.
A study that integrated genomic and clinical data identified 3 distinct clusters of patients with serous epithelial ovarian cancer who do not respond to chemotherapy.
An enhanced recovery program is more cost-effective than usual care in patients undergoing primary cytoreductive surgery for ovarian cancer.
There was no additional protective effect with a third dose of the human papillomavirus vaccine compared with receiving only 2 doses of the vaccine.
Sign Up for Free e-newsletters
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS
- ASCO Endorses SIO Guideline for Integrative Therapies in Breast Cancer
- Seeking Reliable Information on Herbal Products
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Adhering to Cytoreductive Therapy Use May Improve Outcomes in Polycythemia Vera
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|